VCCBH News


2023 VCCBH Pilot Grant Award Recipients

October 24, 2023 by Vermont Center of Cardiovascular and Brain Health

These awards, supported wholly by funds from UVM entities, provide $200,000 over 2 years to fund meritorious research from early career faculty. We are very grateful to Deans from the Colleges of Medicine, Agriculture and Life Sciences, Nursing & Health Sciences, Arts & Sciences, Engineering & Mathematical Sciences, LCOM Deans Office, and the Graduate College, as well as the Cardiovascular Research Institute of Vermont, for their support of this program. In addition, we would like to acknowledge matching fund support from the Departments of Pharmacology and Neurological Sciences.

These awards, supported wholly by funds from UVM entities, provide $200,000 over 2 years to fund meritorious research from early career faculty. We are very grateful to Deans from the Colleges of Medicine, Agriculture and Life Sciences, Nursing & Health Sciences, Arts & Sciences, Engineering & Mathematical Sciences, LCOM Deans Office, and the Graduate College, as well as the Cardiovascular Research Institute of Vermont, for their support of this program. In addition, we would like to acknowledge matching fund support from the Departments of Pharmacology and Neurological Sciences.

Pilot Project Leaders: 

Dr. Nicholas Klug is an Assistant Professor, Research Scholar Track, in the Department of Pharmacology and is a Pipeline Investigator in our Center. His current research centers on the role capillary pericytes and endothelial cells play in sensing and signaling within their respective tissues, such as the central nervous system or meninges to determine how ion channels and associated signaling pathways regulate cerebral blood flow, vascular inflammation, and overall tissue homeostasis. 

Dr. Adam Sprouse-Blum is an Assistant Professor of Neurological Sciences, attending physician, a PhD candidate in Clinical & Translational Science and Pipeline Investigator in our Center. His current research centers on understanding migraine pathophysiology through both human and animal studies with the goal of translating these findings into clinical use.

Project Description

Migraine is a neurovascular disorder and the second leading cause of global disability. Unfortunately, the pathophysiology of migraine is incompletely understood, which has hampered our ability to effectively treat it. One of the largest unanswered questions that remains is, where does the head pain of migraine come from? Current theories suggest the head pain of migraine results from changes that occur in the dura mater. The dura is a protective layer that surrounds the brain and spinal cord. It contains a dense network of tiny blood vessels, called capillaries. This dense capillary network provides an enormous surface area in which head pain in migraine may be detected or transmitted, possibly through actions of pericytes – small cells that line capillaries and regulate their diameter and permeability. In this study, we will begin to examine the role dural capillaries may play in migraine pathophysiology utilizing modern imaging and electrophysiology techniques to measure capillary changes before and after application of CGRP or PACAP, molecules that have been implicated in migraine pathophysiology and that are targets for several novel migraine-specific medications.

 



Recent Stories and Publications Featuring VCCBH Members


Target ALS LinkedIn Post Featuring Research by Dr. Kathryn H. Morelli, PhD

Posted January 4, 2025

"ALS is a devastating disease, but researchers like Kathryn H. Morelli, Ph.D., a Target ALS Springboard Fellow and now an assistant professor at the University of Vermont, are driving innovations that bring us closer to effective treatments. Focused on developing RNA-targeted therapies for C9orf72 ALS, one of the most common genetic causes of the disease, Kathy’s work showcases the critical importance of collaboration, cutting-edge tools, and determination..."

Advancing ALS Research with Stem Cell Resources and Targeted Reagents: The Role of Target ALS in the Quest for Effective Treatment

Posted January 4, 2025

"ALS is a devastating neurodegenerative disease, and while there is no cure, ongoing research continues to offer hope for more effective treatments. An individual at the forefront of these efforts is Dr. Kathryn Morelli, an assistant professor in the Department of Neurological Sciences at the University of Vermont’s Larner College of Medicine, whose research aims to address the complex challenges of ALS, building on work she did with her postdoctoral mentor Dr. Gene Yeo. Working closely with Abby Kirch, a PhD student in her lab, Kathy and her team are focused on developing RNA-targeted therapies for ALS, particularly for the C9ORF72 mutation, one of the most common genetic causes of the disease..."

Larner College of Medicine Dean's Newsletter, Accolades and Accomplishments

Posted December 4, 2024

"On November 16, Larner Assistant Professor of Medicine Debora Kamin Mukaz, Ph.D., M.S., moderated a panel on science policy advocacy titled “How can we engage scientists from historically underrepresented backgrounds in policymaking and advocacy?” at the American Heart Association’s Scientific Sessions 2024 conference in Chicago. The panelists were AHA President Keith Churchwell, M.D.; past AHA President Michelle Albert, M.D., M.P.H.; Emelia Benjamin, M.D., Sc.M., associate provost and professor of medicine and epidemiology at Boston University; and Carl Streed, Jr., M.D., M.P.H., associate professor of medicine at Boston University..."

Research on spider brain leads to groundbreaking Alzheimer’s discovery

Posted December 3, 2024

"Neurodegeneration in spider brain leads Vermont neuroscientists to groundbreaking discovery in Alzheimer’s-affected human brains 
Vermont Business Magazine Researchers from Saint Michael’s College and the University of Vermont have made a groundbreaking new discovery that provides a better understanding of how Alzheimer’s disease develops in the human brain..."

Larner College of Medicine Dean's Newsletter, Accolades and Accomplishments

Posted October 23, 2024

"In a recent paper published in Nature Communications titled “Endothelial Piezo1 Channel Mediates Mechano-Feedback Control of Brain Blood Flow,” Osama Harraz, Ph.D., Bloomfield Early Career Professor in Cardiovascular Research and assistant professor of pharmacology at the Robert Larner, M.D. College of Medicine, and his team of researchers from American and European institutions reveal that Piezo1, a lesser-understood protein, acts as a “brake” system, helping blood flow return to normal after neural activity..."

The association of leptin and incident hypertension in the reasons for geographic and racial differences in stroke (REGARDS) cohort

Posted October 23, 2024

"Leptin is an adipokine associated with obesity and with hypertension in animal models. Whether leptin is associated with hypertension independent of obesity is unclear. Relative to White adults, Black adults have higher circulating leptin concentration..."

Assessing prenatal and early childhood social and environmental determinants of health in the HEALthy Brain and Child Development Study (HBCD)

Posted October 23, 2024

"The HEALthy Brain and Child Development (HBCD) Study, a multi-site prospective longitudinal cohort study, will examine human brain, cognitive, behavioral, social, and emotional development beginning prenatally and planned through early childhood..."

Health Watch: UVM researchers unlock secrets of brain blood flow in cognitive health

Posted October 16, 2024

"Osama Harraz, Ph.D and his team of researchers at the University of Vermont’s Larner College of Medicine have made a breakthrough that could help in the effort to better understand the causes of dementia and how to stop it..."